Painful diabetic neuropathy: an update

Sharonjeet Kaur, Promila Pandhi, Pinaki Dutta, Sharonjeet Kaur, Promila Pandhi, Pinaki Dutta

Abstract

Diabetes, a silent killer, is a leading cause of neuropathy. Around 50% of diabetic patients develop peripheral neuropathy in 25 years. Painful diabetic neuropathy manifests as burning, excruciating, stabbing or intractable type of pain or presents with tingling or numbness. The pathophysiology of this condition is due to primarily metabolic and vascular factors. There is increase in sorbitol and fructose, glycated endproducts, reactive oxygen species and activation of protein kinase C in the diabetic state. All these factors lead to direct damage to the nerves. The first step in the management of painful diabetic neuropathy is a tight glycaemic control. Currently there is no drug which can halt or reverse the progression of the disease. Most of the therapies prevalent aim at providing symptomatic relief. Antidepressants like tricyclic antidepressants (TCAs) and selective norepinephrine reuptake inhibitors (SNRIs) have good efficacy in controlling the symptoms. Selective serotonin reuptake inhibitors have not shown the same consistent results. Anticonvulsants including pregabalin, gabapentin and lamotrigine have shown good results in the control of symptoms whereas same was not found with carbamazepine, oxcarbazepine and topiramate. Topical agents (capsaicin, topical nitrates and topical TCAs) and local anaesthetics have also been used with good results. Use of opioids and non steroidal anti-inflammatory drugs although common but is not preferable. The newer therapies under studies are NMDA antagonists, aldose reductase inhibitors, neurotropic factors, vascular endothelial growth factor, Gamma linolenic acid, protein kinase C beta inhibitors, immune therapy, hyperbaric oxygen and alpha lipoic acid.

Keywords: Drugs; Painful Diabetic Neuropathy; Pathophysiology; Treatment.

Conflict of interest statement

Competing interests – None

Figures

Fig. 1:
Fig. 1:
Pathophysiology of diabetic neuropathy

References

    1. Holzer SE, Camerota A, Martens L et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther. 1998;20:169–181.
    1. Boulton AJM, Malik RA. Diabetic Neuropathy. Medical Clinics of North America. 1998;82:909–929.
    1. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med. 1998;15:508–514.
    1. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123–134.
    1. Veves A, Manes C, Murray HJ et al. Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care. 1993;16:1187–1189.
    1. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123–128.
    1. Gordois A, Scuffham P, Shearer A et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790–1795.
    1. Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
    1. DCCT Research Group.The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–588.
    1. Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Res. 1994;10:189–224.
    1. Bhadada SK, Sahay RK, Jyotsna VP et al. Diabetic Neuropathy: Current Concepts. Journal of Indian Academy of Clinical Medicine. 2001;2:304–318.
    1. Vinik AI, Kong X, Megerian JT et al. Diabetic nerve conduction abnormalities in the primary care setting. Diabetes Technol Ther. 2006;8:654–662.
    1. Armstrong DG, Lavery LA, Vela SA et al. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. Arch Intern Med. 1998;76:68–71.
    1. Maser RE, Laudadio C, Lenhard MJ et al. A cross-sectional study comparing two quantitative sensory testing devices in individuals with diabetes. Diabetes Care. 1997;20:179–181.
    1. Rodriguez M, Trinajstic E, Munoz P. The tactile circumferential discriminator: an instrument for detecting patients at risk of foot ulceration. Diabetes Care. 1997;20:1799.
    1. Vileikyte L, Hutchings G, Hollis S et al. The tactile circumferential discriminator. A new, simple screening device to identify diabetic patients at risk of foot ulceration. Diabetes Care. 1997;20:623–626.
    1. Dyck PJ. Quantitating severity of neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, editors. Peripheral neuropathy. 3rd ed. Philadelphia: WB Saunders; 1993. pp. 686–697.
    1. Dyck PJ, Karnes J, OBrien PC et al. Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology. 1986;36:1300–1308.
    1. Baron R. Peripheral neuropathic pain: From mechanisms to symptoms. Clin J Pain. 2000;16:S12–S20.
    1. Scadding JW. Development of ongoing activity, mechanosensitivity, and adrenaline sensitivity in severed peripheral nerve axons. Exp Neurol. 1981;73:345–364.
    1. Tsigos C, Reed P, Weinkove C et al. Plasma norepinephrine in sensory diabetic polyneuropathy. Diabetes Care. 1993;16:722–727.
    1. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: A review. Diabet Med. 2003;20:88–98.
    1. Sindrup SH, Otto M, Finnerup NB et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96:399–409.
    1. Max MB, Culnane M, Schafer SC et al. Amitryptiline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37:589.
    1. Sindrup SH, Bach FW, Madsen C et al. Venlafaxine versus imipramine in painful diabetic polyneuropathy: A randomized, controlled trial. Neurology. 2003;60:1284–1289.
    1. Raskin J, Pritchett JL, Wang F et al. A double blind, multicenter trial comparing duloxetine with placebo in the treatment of diabetic peripheral neuropathic pain [abstract]. Diabetes. 2005;54:A126.
    1. Kaur H, 100 D, Bhansali A et al. A comparative trial to evaluate Amitryptyline and Duloxetine in painful diabetic neuropathy. Diabetes Care. 2011
    1. Kochar DK, Jain N, Agarwal RP et al. Sodium valproate in the management of painful neuropathy in type 2 diabetes: a randomized placebo controlled study. Acta Neurol Scand. 2002;106:248–252.
    1. Kochar DK, Rawat N, Agrawal RP et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM. 2004;97:33–38.
    1. Rosenstock J, Tuchman M, La Moreaux L et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain. 2004;110:628–638.
    1. Rosenberg JM, Harrell C, Risitic H et al. The effect of gabapentine on neuropathic pain. Clin J Pain. 1997;13:251–255.
    1. Vinik AI, Tuchman M, Safirstein B et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128:169–179.
    1. Jose VM, Bhansali A, Hota D et al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet. Med. 2007;24:377–383.
    1. The capsaicin study group.Treatment of painful diabetic neuropathy with topical capsaicin: a multicenter, double-blind, vehicle controlled study. Arch Intern Med. 1991;151:2225–2229.
    1. Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: A double-blind placebo controlled crossover study. Diabetes Care. 2002;25:1699–1703.
    1. McCleane GJ. Topical doxepin hydrochloride reduces neuropathic pain: a randomized, double blind, placebo controlled study. Pain Clin. 1999;12:47–50.
    1. Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complication. 2006;20(1):34–39.
    1. Oskarsson P, Iiunggren J-G, Lins P-E. Efficacy and safety of mexilitine in the treatment of painful diabetic neuropathy. The mexilitetine study group. Diabetes Care. 1997;20:1594–1597.
    1. Gilron I, Bailey JM, Tu D et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–1334.
    1. Watson CP, Moulin D, Watt-Watson J et al. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71–78.
    1. Harati Y, Gooch C, Swenson M et al. Double blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842–1846.
    1. Cohen KL, Susanne H. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med. 1987;147:1442–14444.
    1. Abuaisha BB, Constanzi JB, Boulton AJM. Acupuncture for the treatment of chronic painful diabetic neuropathy: A longterm study. Diabetes Res Clin Pract. 1998;39:115–121.
    1. Nelson KA, Park KM, Robinovitz E et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and post herpetic neuralgia. Neurology. 1997;48:1212–1218.
    1. Sang CN, Booher S, Gilron I et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose–response trials. Anesthesiology. 2002;96:1053–1061.
    1. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes. 1997;46(Suppl. z2):S82–S89.
    1. Bril V. Status of current clinical trials in diabetic polyneuropathy. Can J Neurol Sci. 2001;28:191–198.
    1. Mizisin AP, Steinhardt RC, O’Brien JS et al. TX14(A), a prosapos in derived peptide, reverses established nerve disorders in streptozotocin diabetic rats and prevents them in galactose-fed rats. J Neuropathol Exp Neurol. 2001;60:953–960.
    1. Apfel SC, Schwartz S, Adornato BT et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA. 2000;284:2215–2221.
    1. Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest. 2001;107:1215–1218.
    1. Schratzberger P, Walter DH, Rittig K et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest. 2001;107:1083–1092.
    1. Keen H, Paxan J, Allawi J et al. Treatment of diabetic neuropathy with gamma - linoleic acid. Diabetes Care. 1993;16:8–15.
    1. Vinik A, Bril V, Kempler P et al. for the MBBQ Study. Treatment of symptomatic diabetic peripheral neuropathy with protein kinase CB inhibitor ruboxistaurin mesylate during a 1-year randomized, placebo-controlled, doubleblind clinical trial. Clin Therapeut. 2005;27:1164–1180.
    1. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol. 1995;52:1053–1061.
    1. Barada A, Reljanovic M, Milicevic Z et al. Proximal diabetic neuropathy: response to immunotherapy [abstract]. Diabetes. 1999;48(Suppl 1):A148.
    1. Bloomgarden ZT. Diabetic Neuropathy. Daibetes Care. 2008;31:616–621.
    1. Reljanovic M, Reichel G, Rett K et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): A two year multicentre randomized double blind placebocontrolled trial (ALADIN II). Free Radic Res. 1999;31:171–179.
    1. Ametov AS, Barinov A, Dyck PJ et al. SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alphalipoic acid: The SYDNEY trial. Diabetes Care. 2003;26:770–776.
    1. Malik RA, Williamson S, Abbott C et al. Effect of angiotensin-converting- enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet. 1998;352(9145):1978–1981.
    1. Bril V, England J, Franklin GM Evidence based guideline: Treatment of painful diabetic neuropathy. Apr 11, 2011. e-Pub ahead of print on. at.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi